Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US6699503 | APGDI | Hydrogel-forming sustained-release preparation |
Sep, 2013
(10 years ago) | |
US6346532 | APGDI | Amide derivatives or salts thereof |
Oct, 2018
(5 years ago) | |
US6562375 | APGDI | Stable pharmaceutical composition for oral use |
Aug, 2020
(3 years ago) | |
US6346532 (Pediatric) | APGDI | Amide derivatives or salts thereof |
Sep, 2022
(1 year, 7 months ago) | |
US7982049 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(6 months ago) | |
US8835474 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(6 months ago) | |
USRE44872 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Nov, 2023
(6 months ago) | |
US7342117 | APGDI | α-form or β-form crystal of acetanilide derivative |
Nov, 2023
(6 months ago) | |
US7750029 | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
Dec, 2023
(4 months ago) | |
US7982049 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(2 days ago) | |
USRE44872 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(2 days ago) | |
US8835474 (Pediatric) | APGDI | Remedy for overactive bladder comprising acetic acid anilide derivative as the active ingredient |
May, 2024
(2 days ago) | |
US7342117 (Pediatric) | APGDI | α-form or β-form crystal of acetanilide derivative |
May, 2024
(2 days ago) | |
US8772315 | APGDI | Pharmaceutical composition for treating overactive bladder |
Oct, 2028
(4 years from now) | |
US8772315 (Pediatric) | APGDI | Pharmaceutical composition for treating overactive bladder |
Apr, 2029
(4 years from now) | |
US11707451 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(5 years from now) | |
US10842780 | APGDI | Pharmaceutical composition for modified release |
Sep, 2029
(5 years from now) | |
US11707451 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) | |
US10842780 (Pediatric) | APGDI | Pharmaceutical composition for modified release |
Mar, 2030
(5 years from now) |
Myrbetriq is owned by Apgdi.
Myrbetriq contains Mirabegron.
Myrbetriq has a total of 19 drug patents out of which 13 drug patents have expired.
Expired drug patents of Myrbetriq are:
Myrbetriq was authorised for market use on 28 June, 2012.
Myrbetriq is available in tablet, extended release;oral dosage forms.
Myrbetriq can be used as for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, administration of an extended release tablet for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency, treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency, administration of an extended release tablet for the treatment of neurogenic detrusor overactivity (ndo) in pediatric patients aged 3 years and older and weighing 35 kg or more, use in combination with the muscarinic antagonist solifenacin succinate for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Drug patent challenges can be filed against Myrbetriq from 26 September, 2023.
The generics of Myrbetriq are possible to be released after 28 March, 2030.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Indication(I-855) | Mar 25, 2024 |
Pediatric Exclusivity(PED) | Sep 25, 2024 |
New Indication(I-777) | Apr 27, 2021 |
New Chemical Entity Exclusivity(NCE) | Jun 28, 2017 |
Drugs and Companies using
MIRABEGRON ingredient